AHPA SEC filings, in plain English
Everything Avista Public Acquisition Corp. II has filed with the SEC that we hold — 40 filings, newest first, 4 with a plain-English summary of what changed and why it matters. Every row links to the primary document on EDGAR, so you can check the source rather than trust us.
The feed
live EDGAR captureNew filings appear here within minutes of hitting EDGAR; summaries follow once the pipeline has read them.
What changed: OmniAb (OABI), the post-merger operating company from Avista Public Acquisition Corp. II, reported Q2 2026 revenue of $13.4M (up from $3.9M YoY) and raised full-year 2026 revenue guidance to $32-36M from $28-33M. Cash and short-term investments stood at $52.0M as of June 30, 2026. Why it matters: This is a routine quarterly earnings release for the post-deal entity with no SPAC-specific mechanics (redemptions, extensions, trust value, or sponsor activity) involved. The SPAC is closed and this filing is purely operational.
What changed: OmniAb (formerly AHPA) filed its Q2 2026 10-Q showing revenue of $13.4M (up 244% YoY) and net loss of $5.9M (improved from $15.9M), with $52.0M in cash and short-term investments. The company has 145.4M shares outstanding, 19.0M SPAC-era warrants (public + private + forward + backstop) at $11.50 expiring Nov 1, 2027, and 16.3M earnout shares vesting at $12.50/$15.00 VWAP triggers that remain unvested. Why it matters: The SPAC deal closed in Nov 2022 and this is a routine post-combination quarterly report; no redemption, extension, or trust-related events are present. Earnout shares and warrants remain outstanding but are far out-of-the-money given the stock's recent trading levels (PIPE priced at $1.40 in Aug 2025), making vesting unlikely before the Nov 2027 expiration.
What changed: OmniAb, Inc., the Avista Public Acquisition Corp. II successor, appointed Amechi Nwachuku, 51, as Chief Operating Officer effective July 13, 2026. He was Vice President, Global Commercial, Genetic Sciences at Thermo Fisher Scientific to April 2025, Senior Vice President, Global Commercial at SCIEX, and held commercial roles at Beckman Coulter Diagnostics, J&J Diabetes Care and Bayer. His offer letter provides an initial annual base salary of $445,000, an annual target bonus of 45% of base salary prorated for 2026, and a $20,000 signing bonus. Why it matters: Hiring a commercial operator rather than a scientist into the COO role signals a shift toward revenue execution at a licensing-model biotech, and the compensation is modest by de-SPAC standards — $445,000 base with a 45% target bonus and a $20,000 signing bonus, with no large equity grant disclosed in the captured text. That restraint matters for former AHPA holders because outsized new-hire equity packages are the main non-financing source of dilution at companies this size.
What changed: OmniAb, Inc., the successor to Avista Public Acquisition Corp. II, called its 2026 annual meeting for Wednesday, June 17, 2026 at 8:00 a.m. Pacific Time, held in person at the company's headquarters at 5980 Horton Street, Suite 600, Emeryville, California, record date April 23, 2026. The related-party disclosure covers Avista entities including ACP V Offshore and options to purchase 40,000 shares of common stock issued to former director Joshua Tamaroff, who on resignation assigned all rights to an Avista affiliate controlled by Mr. Dean and Mr. Burgstahler. Why it matters: Unusually for this cohort the meeting is held in person rather than virtually, which raises the practical bar for retail participation. The substantive item is that the SPAC sponsor's economics persist post-deal: sponsor warrants that the company cannot redeem in any scenario, plus director options reassigned to an Avista affiliate on resignation, leave the original sponsor group holding non-callable dilution against public holders indefinitely.
combination deadlinenothing moved · 1 with no prior record of ours
- Combination deadline
- 2022-03-02 · unchanged
The clause “4 — — — — 27,084 50,105 2/18/2025 — — — — 56,250 104,063 (1) At the time of the Business Combination, each outstanding Ligand equity award granted to our named executive officers prior to March 2, 2022 was split into two equity awards-a”…
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
mandate languagenothing moved · 1 with no prior record of ours
- Mandate language
- focus our efforts on the discovery of antibodies for our par… · unchanged
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
In plain English
Redemption deadlinethe last day to hand shares back for cash
Set by the filing that calls the meeting. Tender after it and the company is under no obligation to pay you the trust value.
Cash in trust / trust per sharethe cash the company is holding for each public share
Filed quarterly in the 10-Q's XBRL. It earns interest between filings, so the figure on a given day is slightly higher than the last filed one — where we show that we label it an estimate.
Accession numberthe SEC's unique id for one filing
Every figure on this page carries the accession of the filing that states it, so you can open the primary document rather than trust us.